Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
The CCTG HN.9 study has been centrally activated in Canada, as of January 31.
HN.9 is a Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC), 2018.
The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Lung Disease Site Committee Executive and the Quality of Life Committee.
The 2018 Clinical Trials Conference hosted by CTO – taking place March 27-28, 2018 at the Sheraton Hotel in Toronto – is an interactive and collaborative 2-day event that brings together over 350 people from industry, research, ethics, healthcare, non-profit, government and academia to exchange ideas, build relationships, and develop new strategies with respect to improving clinical trials and bringing more clinical trials to Ontario.
The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) have announced a multi-year collaboration to develop and conduct clinical trials in immunotherapy. There is an urgent need to collaborate on clinical trials and translational research and to unite leading experts.
The preferred candidates will have a combination of academic and clinical experience, with demonstrated clinical expertise in family medicine, will exhibit strong potential for innovative and scholarly research, and provide evidence of an ability to work in an interdisciplinary, collaborative environment. Clinical responsibilities will be based at the Queen’s Family Health Team in Kingston and include taking call approximately one (1) night per month and three (3) weekends per year.
Online citations of previously published CCTG studies MA.27 and OV.21
